OrthoDx Information

OrthoDx is transforming orthopaedic infection diagnosis through genomic and immune‑response technology. The company specializes in rapid molecular diagnostics that analyze gene expression to distinguish infectious from non‑infectious joint pain. Its team blends expertise in orthopaedic surgery, molecular genomics, regulatory science, and global commercial strategy, positioning OrthoDx as a leader in next‑generation orthopaedic diagnostics. Synvichor, developed by OrthoDx, is the world’s first genomic PCR test capable of differentiating infectious vs. inflammatory joint pain within two hours, achieving up to 95% predictive accuracy. Synvichor enables clinicians to rapidly identify patients who require urgent treatment for infection and safely manage non‑infectious cases in the community. Available for both native and prosthetic joints, Synvichor sets a new diagnostic standard and has the potential to deliver significant cost savings and improve hospital capacities on a global scale.